The Hemopurifier is an extracorporeal (i.e., outside of the body) blood filtration device designed to selectively remove harmful particles from the circulatory system using lectin affinity agents.
In 2008, the company conducted an in vitro study demonstrating that the Hemopurifier effectively bound and removed the monkeypox virus.
The study indicated that the Hemopurifier removed 44% of the monkeypox virus in the first hour of testing, 82% after six hours, and 98% after 20 hours.
"We believe that the Hemopurifier's ability to bind the current MPXV strain should not be affected because the mutations present in this strain do not change the mannose sugar in the viral envelope, which is recognized by the GNA within the Hemopurifier resin," the company said.
Aethlon says it has contacted the FDA and confirmed the process by which it could provide the Hemopurifier to requesting physicians for single-patient emergency use.
The company plans to submit a pre-Emergency Use Authorization package to the FDA.
Aethlon Medical held a cash balance of approximately $14.9 million.
Price Action: AEMD shares are up 14.50% at $1.50 during the market session on the last check Tuesday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.